Article
Raloxifene pharmacodynamics is influenced by genetic variants in the RANKL/RANK/OPG system and in the Wnt signaling pathway.
Drug metabolism and drug interactions - 1 Jan 2014
Mencej-Bedrač Simona, Zupan Janja, Mlakar Simona Jurković, Zavratnik Andrej, Preželj Janez, Marc Janja
Abstract excerpt
BACKGROUND: Raloxifene is a selective estrogen receptor (ER) modulator (SERM) used for the treatment of osteoporosis. However, its efficacy and also its safety vary greatly among treated patients, and it might be influenced by the individuals' genetic background. As the receptor activator of the nuclear factor κB (RANK) ligand (RANKL)/RANK/osteoprotegerin (OPG) system is essential for osteoclastogensis and Wnt...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
